Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Eugene Jon Koay

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7675-3461; OpenAlex author ID A5015539463, A5026500137, A5129362302; NIH RePORTER profile ID 11832207. Sources: funder_awards.

Their work

Papers
87 (first author 3, last author 11)
Trials
4 (principal investigator on 4)
Grants
2
Labs led
1
Collaborators
308
Papers, trials and grants by year

2014: 3 papers, 1 grant · 2015: 1 paper, 2 trials · 2016: 4 papers · 2017: 5 papers · 2018: 11 papers · 2019: 10 papers · 2020: 9 papers, 1 trial · 2021: 12 papers · 2022: 6 papers · 2023: 8 papers, 1 trial · 2024: 7 papers · 2025: 7 papers · 2026: 4 papers, 1 grant

Papers 50 of 87

  1. Machine learning-based multimodal biomarkers enable accurate diagnosis and early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-29548-4↗
  2. Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag423↗
  3. Assessment of impending pancreatic cancer in a cohort of new onset diabetes on basis of biomarker trajectory Co-author DOI 10.64898/2026.08.06.26359908↗
  4. KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adeno… Co-author DOI 10.64898/2026.10.05.756824↗
  5. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  6. Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12029-024-01145-0↗
  7. Clinical Applications of Quantitative Imaging and Artificial Intelligence for Pancreatic Cance. Last author DOI 10.1016/j.semradonc.2025.07.003↗
  8. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae182↗
  9. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006269↗
  10. A spatial atlas of chemoradiation therapy in pancreatic cancer identifies cellular and microenvironmental determinants of persister populations Last author DOI 10.1101/2025.06.20.660757↗
  11. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-025-01696-0↗
  12. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Last author DOI 10.1002/cam4.7434↗
  13. Blood-Based microRNA Biomarker Signature of Early-Stage Pancreatic Ductal Adenocarcinoma With Lead-Time Trajectory in Prediagnostic Samples. Co-author DOI 10.1016/j.gastha.2024.08.002↗
  14. Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early phase validation studies. Co-author DOI 10.1016/j.pan.2024.10.012↗
  15. A Multi-Institutional Safety and Feasibility Study Exploring the Use of Hydrogel to Create Spatial Separation between the Pancreas and Duodenum in Patients wit… Last author DOI 10.1016/j.prro.2023.11.011↗
  16. Retraction Note: Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarci… Co-author DOI 10.1038/s41418-024-01387-2↗
  17. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II T… Co-author DOI 10.1200/jco.24.00081↗
  18. The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.3390/cancers16193312↗
  19. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗
  20. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.1097/pas.0000000000002013↗
  21. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000005184↗
  22. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Ran… Co-author DOI 10.1097/sla.0000000000005878↗
  23. Potential of artificial intelligence in the risk stratification for and early detection of pancreatic cancer. Last author DOI 10.20517/ais.2022.38↗
  24. Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy. Co-author DOI 10.3390/cancers15092608↗
  25. Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neo… Co-author DOI 10.3390/cancers15123231↗
  26. Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiation Therapy in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers15225355↗
  27. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Last author DOI 10.1016/j.ctro.2021.12.012↗
  28. Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. Co-author DOI 10.1016/j.ctro.2022.04.007↗
  29. Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. Last author DOI 10.1016/j.ijrobp.2022.04.044↗
  30. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  31. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci151604↗
  32. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. Last author DOI 10.1186/s12885-021-09095-7↗
  33. CT features predictive of nodal positivity at surgery in pancreatic cancer patients following neoadjuvant therapy in the setting of dual energy CT. Co-author DOI 10.1007/s00261-020-02917-5↗
  34. Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.adro.2020.11.006↗
  35. Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. Co-author DOI 10.1016/j.adro.2021.100763↗
  36. Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite … Co-author DOI 10.1016/j.ctro.2021.02.004↗
  37. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.11.003↗
  38. GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first. Co-author DOI 10.1016/j.pan.2021.08.006↗
  39. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003442↗
  40. Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Co-author DOI 10.1158/2159-8290.cd-20-1228↗
  41. DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis. Co-author DOI 10.1172/jci.insight.146133↗
  42. Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. Co-author DOI 10.3389/fonc.2021.628155↗
  43. Role of 3D Volumetric and Perfusion Imaging for Detecting Early Changes in Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.678617↗
  44. Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13205168↗
  45. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2020.2286↗
  46. Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Co-author DOI 10.1016/j.prro.2020.01.012↗
  47. Early detection of pancreatic cancer. Co-author DOI 10.1016/s2468-1253(19)30416-9↗
  48. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003763↗
  49. Diversity Across the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by Network-Anchored Functional Genomics Co-author DOI 10.1101/2020.09.17.302034↗
  50. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08427-4↗

Trials 4

  1. New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study Principal investigator NCT04481204↗
  2. NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer Principal investigator NCT04484909↗
  3. Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer Principal investigator NCT02361320↗
  4. Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer Principal investigator NCT02394535↗

Grants 2

  1. Circulating Biomarkers and Imaging for Early Detection of Pancreatic Cancer U01CA214263↗
  2. Changes in mass transport as a biomarker of response in pancreatic cancer AWARD pancan:2014-eugene-koay-md-phd-changes-in-mass-transport-as-a-biomarker

Closest collaborators

The 25 strongest of 308 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthew H. G. Katz · 46 shared papers, 2014–2026 · strength 5.03
  2. Anirban Maitra · 39 shared papers, 2014–2026 · strength 4.70
  3. Robert A. Wolff · 38 shared papers, 2014–2026 · strength 4.13
  4. Ching-Wei David Tzeng · 25 shared papers, 2017–2025 · strength 3.32
  5. Michael P. Kim · 28 shared papers, 2016–2025 · strength 3.27
  6. Naruhiko Ikoma · 17 shared papers, 2020–2026 · strength 2.37
  7. Shubham Pant · 17 shared papers, 2019–2026 · strength 2.37
  8. Laura R. Prakash · 20 shared papers, 2016–2025 · strength 2.17
  9. Huamin Wang · 23 shared papers, 2014–2025 · strength 2.13
  10. Jeffrey E. Lee · 23 shared papers, 2014–2025 · strength 2.12
  11. Cullen M. Taniguchi · 20 shared papers, 2018–2024 · strength 2.05
  12. Ethan Bernard Ludmir · 13 shared papers, 2021–2026 · strength 2.00
  13. Joseph M. Herman · 20 shared papers, 2017–2024 · strength 1.98
  14. Albert C. Koong · 15 shared papers, 2018–2025 · strength 1.90
  15. Jason B. Fleming · 23 shared papers, 2014–2024 · strength 1.68
  16. Gauri Rajani Varadhachary · 21 shared papers, 2014–2022 · strength 1.55
  17. Subrata Sen · 3 shared papers, 1 shared grant, 2019–2026 · strength 1.48
  18. Eric Peter Tamm · 18 shared papers, 2014–2022 · strength 1.48
  19. Michael James Overman · 14 shared papers, 2016–2026 · strength 1.46
  20. Manoop S. Bhutani · 12 shared papers, 2017–2025 · strength 1.46
  21. Ann McNeill Killary · 2 shared papers, 1 shared grant, 2024–2026 · strength 1.41
  22. Ya’an Kang · 16 shared papers, 2014–2024 · strength 1.28
  23. Priya Bhosale · 15 shared papers, 2014–2022 · strength 1.23
  24. Dan Zhao · 7 shared papers, 2023–2025 · strength 1.14
  25. Brandon George Smaglo · 6 shared papers, 2023–2026 · strength 1.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.